The Similarity Between Aspirin Treatment and the Lack of Response to Epinephrine and the Frequency of Aspirin Resistance in Healthy Males

Abstract

Objectives: The lack of response of platelets against epinephrine has been discovered with a frequency of 14% to 40% in previous studies. There are studies that have demonstrated the effect of aspirin on platelets may resemble the lack of response to epinephrine. In this study, the extent of the effects of aspirin treatment on aggregation and secretion in healthy males with a lack of response to epinephrine and the frequency of aspirin resistance were investigated. Methods: Blood samples were collected at the beginning and at the end of a 10-day aspirin usage in 52 healthy males. Epinephrine, adenosine diphosphate (ADP), collagen, arachidonic acid (AA) and thrombin aggregations, and adenosine triphosphate (ATP) secretion were studied. Participants were assigned to nonresponder (<20%), semiresponder (20%-60%), and responder (>60%) groups, depending on their maximum aggregation responses to epinephrine. Participants who displayed an aggregation to AA at the end of the aspirin treatment were accepted to be aspirin resistant. Results: Of the 52 participants, 4 were found to be nonresponders and 3 of 52 of the participants were found to be semiresponders. Although the lack of response to epinephrine and aspirin treatment displayed similarities in aggregations using epinephrine, ADP, collagen, and thrombin, they differed in aggregations using AA and for ATP secretion. The ratio of aspirin resistance was determined to be 4:52. Conclusions: The observation of AA aggregation in the participants with a lack of response to epinephrine demonstrates that epinephrine nonresponse cannot substitute aspirin treatment. The fact that aspirin resistance is observed in healthy males supports the view that aspirin resistance exists even before the first usage.

Keywords

platelets optical aggregometer epinephrine aspirin resistance

References

Brass LF The molecular basis of platelet activation. In: Hoffman R , Benz EJ , Shattil SJ , Furie B , et al., eds. Hoffman: Hematology: Basic Principles and Practice. 4th ed. Philadelphia, PA: Elsevier; 2005. Pages: 1793-1804.

Kambayashi J. , Shinoki N. , Nakamura T. , et al. Prevalence of impaired responsiveness to epinephrine in platelets among Japanese. Thromb Res. 1996;81(1):85-90.

Nakamura T. , Ariyoshi H. , Kambayashi J. , et al. Signal transduction system in epinephrine stimulated platelets; comparison between epinephrine sensitive and insensitive platelets. Thromb Res. 1997;85(2):83-93.

Nakahashi TK , Kambayashi J. , Nakamura T. , et al. Platelets in nonresponders to epinephrine stimulation showed reduced response to ADP. Thromb Res. 2001;104(2):127-135.

Theodoropoulos I. , Christopoulos C. , Metcalfe P. , Dimitriadou E. , Economopoulos P. , Loucopoulos D. The effect of human platelet alloantigen polymorphisms on the in vitro responsiveness to adrenaline and collagen. Br J Haematol. 2001;114(2):387-393.

Choi JW Incidence of nonresponsiveness to epinephrine in platelets from healthy humans . Acta Haematol. 2002;108(2):106-108.

Pyo MK , Yun-Choi HS , Hong YJ Apparent heterogeneous responsiveness of human platelet rich plasma to catecholamines . Platelets. 2003;14(3):171-178.

Sagdilek E. , Buyukcoskun NI , Ozluk K. The investigation of platelets’ response to epinephrine using optical aggregometer and PFA-100. Uludağ Üniversitesi Tip Fakültesi Dergisi. 2006; 32(1):15-20.

Sagdilek E. , Korkmaz A. , Oter S. , et al. Evaluation of platelet function and lack of response to epinephrine in healthy young-adult men. Gulhane Med J. 2006;48(3):146-150.

10.

Yang J. , Wu J. , Kowalska MA , et al. Loss of signaling through the G protein, Gz, results in abnormal platelet activation and altered responses to psychoactive drugs. Proc Natl Acad Sci U S A. 2000;97(18):9984-9989.

11.

Antithrombotic Trialists ’ Collaboration. Collaborative meta-analysis of randomised trials of antiplatelet therapy for prevention of death, myocardial infarction and stroke in high risk patients. Br Med J. 2002;324(7329):71-86.

12.

Gum PA , Kottke-Marchant K. , Poggio ED , et al. Profile and prevalence of aspirin resistance in patients with cardiovascular disease. Am J Cardiol. 2001 ;88(3):230-235.

13.

Josie AC-K , Pritesh JG Possible mechanisms of aspirin resistance . J Thromb Thrombolysis . 2002;13(1):49-56.

14.

Patricia AH Aspirin resistance. Ann Pharmacother . 2002;36(10): 1620-1624.

15.

Michelson AD , Frelinger AL , Furman MI Resistance to antiplatelet drugs. Eur Heart J Suppl. 2006;8(suppl G):G53-G58.

16.

Avcu F. , Ural AU , Cetin T. , Nevruz O. Effects of bortezomib on platelet aggregation and ATP release in human platelets, in vitro. Thromb Res. 2008;121(4):567-571.

17.

Sagdilek E. , Buyukcoskun NI , Ozluk K. Evaluation of platelet function and lack of response to epinephrine in pregnant women. Int J Lab Hematol . 2007;29(4):302-309.

18.

Storey RF , Heptinstall S. Laboratory investigation of platelet function. Clin Lab Haem . 1999;21(5):317-329.

19.

Yee DL , Sun CW , Bergeron AL , Dong J. , Bray PF Aggregometry detects platelet hyperactivity in healthy individuals . Blood. 2005; 106(8):2723-2729.

20.

Gurbel PA , Bliden KP , DiChiara J. , et al. Evaluation of dose-related effects of aspirin on platelet function: results from the Aspirin-Induced Platelet Effect (ASPECT) study. Circulation. 2007;115(25):3156-3164.

21.

Gurbel PA , Becker RC , Mann KG , Steinhubl SR , Michelson AD Platelet function monitoring in patients with coronary artery disease . J Am Coll Cardiol. 2007;50(19):1822-1834.